Epstein-Barr virus—recent advances

Epstein, 1964, Virus particles in cultured lymphoblasts from Burkitt's lymphoma, Lancet, 1, 702, 10.1016/S0140-6736(64)91524-7 Raab-Traub, 1991, Epstein-Barr virus infection in carcinoma of the salivary gland, J Virol, 65, 7032, 10.1128/JVI.65.12.7032-7036.1991 Bonnet, 1999, Detection of Epstein-Barr virus in invasive breast cancers, J Natl Cancer Inst, 91, 1376, 10.1093/jnci/91.16.1376 Sugarawa, 1999, Detection of Epstein-Barr virus (EBV) in hepatocellular carcinoma tissue: a novel EBV latency characterized by the absence of EBV-encoded small RNA expression, Virology, 256, 196, 10.1006/viro.1999.9619 Leywraz, 1985, Association of Epstein-Barr virus with thymic carcinoma, New Engl J Med, 213, 1296, 10.1056/NEJM198505163122006 Crawford, 2001, Biology and disease associations of Epstein-Barr virus, Phil Trans R Soc Lond B, 356, 461, 10.1098/rstb.2000.0783 Henle, 1969, Antibodies to Epstein-Barr virus in Burkitt's lymphoma and control groups, J Nat Cancer Inst, 43, 1147 Babcock, 1998, EBV persistence in memory B cells in vivo, Immunity, 9, 395, 10.1016/S1074-7613(00)80622-6 Thorley-Lawson, 1996, Epstein-Barr virus and the B cell: that's all it takes, Trends Microbiol, 4, 204, 10.1016/S0966-842X(96)90020-7 Yao, 1985, A reexamination of the Epstein-Barr virus carrier state in healthy seropositive individuals, Int J Cancer, 35, 35, 10.1002/ijc.2910350107 Niederman, 1976, Infectious mononucleosis. Epstein-Barr-virus shedding in saliva and the oropharynx, N Engl J Med, 29, 1355, 10.1056/NEJM197606172942501 Fleisher, 1979, Primary infection with Epstein-Barr virus in infants in the United States: clinical and serologic observations, J Infect Dis, 139, 553, 10.1093/infdis/139.5.553 Fleisher, 1981, Pasqariello. Intrafamilial transmission of Epstein-Barr virus infections, J Pediatr, 98, 16, 10.1016/S0022-3476(81)80525-2 Gratama, 1990, EBNA size polymorphism can be used to trace Epstein-Barr virus spread within families, J Virol, 64, 4703, 10.1128/JVI.64.10.4703-4708.1990 Biggar, 1978, Primary Epstein-Barr virus infections in African infants. II. Clinical and serological observations during seroconversion, Int J Cancer, 22, 244, 10.1002/ijc.2910220305 Hallee, 1974, Infectious mononucleosis at the United States Military Academy. A prospective study of a single class over four years, Yale J Biol Med, 3, 182 1971, Infectious mononucleosis and its relationship to EB virus antibody. A joint investigation by university health physicians and PHLS laboratories, BMJ, 4, 643, 10.1136/bmj.4.5788.643 Niederman, 1970, Prevalence, incidence and persistence of EB virus antibody in young adults, N Engl J Med, 282, 361, 10.1056/NEJM197002122820704 Sawyer, 1971, Prospective studies of a group of Yale University freshmen. 1. Occurrence of infectious mononucleosis, J Infect Dis, 123, 263, 10.1093/infdis/123.3.263 Israele, 1991, Excretion of the Epstein-Barr virus from the genital tract of men, J Infect Dis, 163, 1341, 10.1093/infdis/163.6.1341 Sixbey, 1986, A second site for Epstein-Barr virus shedding: the uterine cervix, Lancet, 2, 1122, 10.1016/S0140-6736(86)90531-3 Crawford, 2002, Sexual history and Epstein-Barr virus infection, J Infect Dis, 186, 731, 10.1086/342596 Gerber, 1969, Association of EB-virus infection with the post-perfusion syndrome, Lancet, 1, 593, 10.1016/S0140-6736(69)91532-3 Alfieri, 1996, Epstein-Barr virus transmission from a blood donor to an organ transplant recipient with recovery of the same virus strain from the recipient's blood and oropharynx, Blood, 87, 812, 10.1182/blood.V87.2.812.bloodjournal872812 Cen, 1991, Epstein-Barr virus transmission via the donor organs in solid organ transplantation: polymerase chain reaction and restriction fragment length polymorphism analysis of IR2, IR3 and IR4, J Virol, 65, 976, 10.1128/JVI.65.2.976-980.1991 Haque, 1996, Transmission of donor Epstein-Barr virus (EBV) in transplant organs causes lymphoproliferative disease in EBV-seronegative recipients, J Gen Virol, 77, 1169, 10.1099/0022-1317-77-6-1169 Zimber, 1986, Geographical prevalence of two types of Epstein-Barr virus, Virology, 154, 56, 10.1016/0042-6822(86)90429-0 Anagnostopoulos, 1995, Morphology, immunophenotype, and distribution of latently and/or productively Epstein-Barr virus-infected cells in acute infectious mononucleosis: implications for the interindividual infection route of Epstein-Barr virus, Blood, 85, 744, 10.1182/blood.V85.3.744.bloodjournal853744 Farrell, 2002, Cell-switching and kissing, Nat Med, 8, 559, 10.1038/nm0602-559 Borza, 2002, Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus, Nat Med, 8, 594, 10.1038/nm0602-594 Faulkner, 2000, The ins and outs of EBV infection, Trends Microbiol, 8, 185, 10.1016/S0966-842X(00)01742-X Perry, 1988, Structure of the crypt epithelium in human palantine tonsils, Acta Otolaryngol, 454, 53, 10.3109/00016488809125005 Babcock, 2000, Tonsillar memory B cells, latently infected with Epstein-Barr virus, express the restricted pattern of latent genes previously found only in Epstein-Barr virus-associated tumors, Proc Natl Acad Sci USA, 97, 12250, 10.1073/pnas.200366597 Gires, 1997, Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule, EMBO J, 16, 6131, 10.1093/emboj/16.20.6131 Kilger, 1998, Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein1, which stimulates an activated CD40 receptor, EMBO J, 17, 1700, 10.1093/emboj/17.6.1700 Zimber-Strobl, 1996, Epstein-Barr virus latent membrane protein 1 (LMP1) is not sufficient to maintain proliferation of B cells but both it and activated CD40 can prolong their survival, EMBO J, 15, 7070, 10.1002/j.1460-2075.1996.tb01098.x Uchida, 1999, Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses, Science, 286, 300, 10.1126/science.286.5438.300 Caldwell, 1998, Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals, Immunity, 9, 405, 10.1016/S1074-7613(00)80623-8 Miyashita, 1995, A novel form of Epstein-Barr virus latency in normal B cells in vivo, Cell, 80, 593, 10.1016/0092-8674(95)90513-8 Wagner, 1992, Detection and quantification of latently infected B lymphocytes in Epstein-Barr virus-seropositive, healthy individuals by polymerase chain reaction, J Clin Microbiol, 30, 2826, 10.1128/JCM.30.11.2826-2829.1992 Qu, 1992, Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes, J Virol, 66, 3715, 10.1128/JVI.66.6.3715-3724.1992 Miyashita, 1997, Identification of the site of Epstein-Barr virus persistence in vivo as a resting cell, J Virol, 71, 4882, 10.1128/JVI.71.7.4882-4891.1997 Miller, 1995, Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases, Immunity, 2, 155, 10.1016/S1074-7613(95)80040-9 Miller, 1994, An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking, Proc Natl Acad Sci USA, 91, 772, 10.1073/pnas.91.2.772 Thorley-Lawson, 2001, Epstein-Barr virus: exploiting the immune system, Nat Rev Immunol, 1, 75, 10.1038/35095584 Crawford, 1986, EB virus induction is associated with B-cell maturation, Immunology, 59, 405 Yates, 1985, Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells, Nature, 313, 812, 10.1038/313812a0 Levitskaya, 1997, Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1, Proc Natl Acad Sci USA, 94, 12616, 10.1073/pnas.94.23.12616 Rickinson, 2001, Epstein-Barr virus, 2575 Moore, 2001, Interleukin-10 and the interleukin-10 receptor, Ann Rev Immunol, 19, 683, 10.1146/annurev.immunol.19.1.683 Cohen, 1999, Epstein-Barr virus BARF1 protein is dispensable for B-cell transformation and inhibits alpha interferon secretion from mononuclear cells, J Virol, 73, 7627, 10.1128/JVI.73.9.7627-7632.1999 Morrison, 2001, Inhibition of IFN-γ signaling by an Epstein-Barr virus immediate-early protein, Immunity, 15, 787, 10.1016/S1074-7613(01)00226-6 Henderson, 1993, Epstein-Barr virus-coded BHRF1 protein, a viral homolgue of Bcl-2, protects human B cells from programmed cell death, Proc Natl Acad Sci USA, 90, 8479, 10.1073/pnas.90.18.8479 Hoagland, 1964, The incubation period of infectious mononucleosis, Am J Public Health, 54, 1699, 10.2105/AJPH.54.10.1699 Schooley, 2000, Epstein-Barr virus (infectious mononucleosis), 1599 Dommerby, 1986, Hepatosplenomegaly in infectious mononucleosis, assessed by ultrasonic scanning, J Laryngol Otol, 100, 573, 10.1017/S0022215100099680 McCarthy, 1964, Cutaneous manifestations of infectious mononucleosis, JAMA, 187, 153, 10.1001/jama.1964.03060150077029 Pullen, 1967, Hypersensitivity reactions to antibacterial drugs in infectious mononucleosis, Lancet, 2, 1176, 10.1016/S0140-6736(67)91893-4 Kerns, 1973, Ampicillin rash in children. Relationship to penicillin allergy and infectious mononucleosis, Am J Dis Child, 125, 187, 10.1001/archpedi.1973.04160020023004 Evans, 1978, Infectious mononucleosis and related syndromes, Am J Med Sci, 276, 325, 10.1097/00000441-197811000-00010 Fleisher, 1983, Limitations of available tests for diagnosis of infectious mononucleosis, J Clin Microbiol, 17, 619, 10.1128/JCM.17.4.619-624.1983 Sumaya, 1985, Epstein-Barr virus infectious mononucleosis in children. II. Heterophil antibody and viral-specific responses, Pediatrics, 75, 1011, 10.1542/peds.75.6.1011 Vidrih, 2001, Positive Epstein-Barr virus heterophile antibody tests in patients with primary human immunodeficiency virus infection, Am J Med, 111, 192, 10.1016/S0002-9343(01)00804-X Horowitz, 1979, Persistent falsely positive rapid tests for infectious mononucleosis, Am J Clin Pathol, 72, 807, 10.1093/ajcp/72.5.807 Wynne Jones, 1994, Human parvovirus B19, 308 Hendry, 1982, Systemic lupus erythematosus presenting as infectious monoucleosis with a false positive monospot test, Lancet, 1, 455, 10.1016/S0140-6736(82)91666-X Okano, 1988, Epstein-Barr virus and human diseases: recent advances in diagnosis, Clin Microbiol Rev, 1, 300, 10.1128/CMR.1.3.300 Henle, 1979, Rheumatoid factor as a cause of positive reactions in tests for Epstein-Barr virus specific IgM antibodies, Clin Exper Immunol, 36, 415 White, 1998, Incidence, risk and prognosis of acute and chronic fatigue syndromes and psychiatric disorders after glandular fever, Br J Psychiatry, 173, 475, 10.1192/bjp.173.6.475 Whiting, 2001, Interventions for the treatment and management of chronic fatigue syndrome. A systematic review, JAMA, 286, 1360, 10.1001/jama.286.11.1360 Pagano, 1983, Acyclovir and Epstein-Barr virus infection, J Antimicrob Chemother, 12, 113, 10.1093/jac/12.suppl_B.113 Andersson, 1986, Effect of acyclovir on infectious mononucleosis: a double-blind, placebo-controlled study, J Infect Dis, 153, 283, 10.1093/infdis/153.2.283 Andersson, 1987, Acyclovir treatment in infectious mononucleosis: a clinical and virological study, Infection, 15, S14, 10.1007/BF01650106 Brandfonbrener, 1986, Corticosteroid therapy in Epstein-Barr virus infection. Effect on lymphocyte class, subset, and response to early antigen, Arch Intern Med, 146, 337, 10.1001/archinte.1986.00360140167024 Straus, 1993, Epstein-Barr virus infections: biology, pathogenesis, and management, Ann Intern Med, 118, 45, 10.7326/0003-4819-118-1-199301010-00009 McGowan, 1992, Guidelines for the use of systemic glucocorticosteroids in the management of selected infections, J Infect Dis, 165, 1, 10.1093/infdis/165.1.1 Sudderick, 1987, Steroids for airway problems in glandular fever, J Laryngol Otol, 101, 673, 10.1017/S0022215100102506 Foss, 1994, Patterns of cytokine gene expression in infectious mononucleosis, Blood, 83, 707, 10.1182/blood.V83.3.707.707 Linde, 1992, Serum levels of lymphokines and soluble cellular receptors in primary Epstein-Barr virus infection and in patients with chronic fatigue syndrome, J Infect Dis, 165, 994, 10.1093/infdis/165.6.994 Callan, 1998, Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo, J Exp Med, 187, 1395, 10.1084/jem.187.9.1395 Kimura, 2001, Clinical and virologic characteristics of chronic active Epstein-Barr virus infection, Blood, 98, 280, 10.1182/blood.V98.2.280 Straus, 1988, The chronic mononucleosis syndrome, J Infect Dis, 157, 405, 10.1093/infdis/157.3.405 Okamura, 2000, Blood stem-cell transplantation for chronic active Epstein-Barr virus with lymphoproliferation, Lancet, 356, 223, 10.1016/S0140-6736(00)02488-0 Kuzushima, 1996, Establishment of anti-Epstein-Barr virus (EBV) cellular immunity by adoptive transfer of virus-specific cytotoxic T lymphocytes from an HLA-matched sibling to a patient with severe chronic active EBV infection, Clin Exp Immunol, 103, 192, 10.1046/j.1365-2249.1996.d01-619.x Bar, 1974, Fatal infectious mononucleosis in a family, N Engl J Med, 290, 363, 10.1056/NEJM197402142900704 Purtilo, 1975, X-linked recessive progressive combined variable immunodeficiency (Duncan's Disease), Lancet, 1, 935, 10.1016/S0140-6736(75)92004-8 Mroczek, 1987, Fatal infectious mononucleosis and virus-associated hemophagocytic syndrome, Arch Pathol Lab Med, 111, 530 Seemayer, 1995, X-linked lymphoproliferative disease: twenty-five years after the discovery, Pediatr Res, 38, 471, 10.1203/00006450-199510000-00001 Hamilton, 1980, Finkelstein GZ, landing B, Grunnet M, Purtilo DT. X-linked lymphoproliferative syndrome registry report, J Pediatr, 96, 669, 10.1016/S0022-3476(80)80735-9 Arkwright, 1998, X linked lymphoproliferative disease in a United Kingdom family, Arch Dis Child, 79, 52, 10.1136/adc.79.1.52 Migliorati, 1994, Treatment of EBV-induced lymphoproliferative disorder with epipodophyllotoxin VP16-213, Acta Pædiatr, 83, 1322, 10.1111/j.1651-2227.1994.tb13030.x Gross, 1996, Cure of X-linked lymphoproliferative disease (XLP) with allogeneic hematopoietic stem cell transplantation (HSCT): report from the XLP registry, Bone Marrow Transplant, 17, 741 Coffey, 1998, Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene, Nat Genet, 20, 129, 10.1038/2424 Sayos, 1998, Notarangelo L, Geha R, Roncarolo MG, Oettgen H, De Vries JE, Aversa G, Terhorst C. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM, Nature, 395, 462, 10.1038/26683 Nichols, 1998, Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome, Proc Natl Acad Sci USA, 95, 13765, 10.1073/pnas.95.23.13765 Sumegi, 2000, Correlation of mutations of the SH2D1A gene and Epstein-Barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease, Blood, 96, 3118 Morra, 2001, Alterations of the X-linked lymphoproliferative disease gene SH2D1A in common variable immunodeficiency syndrome, Blood, 98, 1321, 10.1182/blood.V98.5.1321 Nistala, 2001, Gaspar, Jones AM. X-linked lymphoproliferative disease: three atypical cases, Clin Exp Immunol, 126, 126, 10.1046/j.1365-2249.2001.01599.x Dutz, 2001, Lymphocytic vasculitis in X-linked lymphoproliferative disease, Blood, 97, 95, 10.1182/blood.V97.1.95 Brandau, 1999, Epstein-Barr virus-negative boys with non-Hodgkin lymphoma are mutated in the SH2D1A gene, as are patients with X-linked lymphoproliferative disease (XLP), Hum Mol Genet, 8, 2407, 10.1093/hmg/8.13.2407 Cocks, 1995, A novel receptor involved in T-cell activation, Nature, 376, 260, 10.1038/376260a0 Tangye, 2000, Functional requirement for SAP in 2B4-mediated activation of human natural killer cells as revealed by the X-linked lymphoproliferative syndrome, J Immunol, 165, 2932, 10.4049/jimmunol.165.6.2932 Gaspar, 2002, X-linked lymphoproliferative disease: clinical, diagnostic and molecular perspective, Br J Haematol, 119, 585, 10.1046/j.1365-2141.2002.03851.x Savoie, 1994, Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease, Blood, 83, 2715, 10.1182/blood.V83.9.2715.2715 Lucas, 1996, The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation, Blood, 87, 2594, 10.1182/blood.V87.6.2594.bloodjournal8762594 Nalesnik, 1998, Clinical and pathological features of post-transplant lymphoproliferative disorders (PTLD), Springer Semin Immunopathol, 20, 325, 10.1007/BF00838047 Ho, 1988, The frequency of Epstein-Barr virus infection and associated lymphoproliferative disease after transplantation and its manifestations in children, Transplantation, 45, 719, 10.1097/00007890-198804000-00011 Ho, 1985, Epstein-Barr virus infections and DNA hybidization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection, J Infect Dis, 152, 876, 10.1093/infdis/152.5.876 Stevens, 2001, Nucleic acid-based diagnostic approaches in EBV-associated disease, EBV Rep, 8, 31 Lucas, 1998, Semi-quantitative Epstein-Barr virus polymerase chain reaction analysis of peripheral blood from organ transplant patients and risk for the development of lymphoproliferative disease, Blood, 92, 3977, 10.1182/blood.V92.10.3977 Kimura, 1999, Quantitative analysis of Epstein-Barr virus load by using a realtime PCR assay, J Clin Microbiol, 37, 132, 10.1128/JCM.37.1.132-136.1999 Baldanti, 2000, High levels of Epstein-Barr virus DNA in blood of solid-organ transplant recipients and their value in predicting post-transplant lymphoproliferative disorders, J Clin Microbiol, 38, 613, 10.1128/JCM.38.2.613-619.2000 Hopwood, 2002, Persistent Epstein-Barr virus infection: unrestricted latent and lytic viral gene expression in healthy immunosuppressed transplant recipients, Transplantation, 74, 194, 10.1097/00007890-200207270-00009 Nalesnik, 1988, Clonal chacteristics of posttransplant lymphoproliferative disorders, Transplant Proc, 20, 280 Timms, 2003, Epstein-Barr virus (EBV)-positive post transplant lymphoproliferative disease frequently arises from B cells with randomly mutated or sterile immunoglobulin genes: a mechanistic link with EBV-positive Hodgkin's Disease, Lancet, 361, 217, 10.1016/S0140-6736(03)12271-4 Starzl, 1984, Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy, Lancet, 1, 583, 10.1016/S0140-6736(84)90994-2 Armitage, 1991, Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression, J Heart Lung Transplant, 10, 877 Cook, 1999, Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation, Lancet, 354, 1698, 10.1016/S0140-6736(99)02058-9 Kuehnle, 2000, CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation., Blood, 95, 1502, 10.1182/blood.V95.4.1502.004k40_1502_1505 Verschuuren, 2002, Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse and the complication, Transplantation, 73, 100, 10.1097/00007890-200201150-00019 1999, Rituximab (MabThera): serious infusion-related adverse reactions., Curr Probl Pharmacovigilance, 25, 2 Suzan, 2001, Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder., N Engl J Med, 13, 1000, 10.1056/NEJM200109273451315 Sharma, 2000, Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab., Blood, 96, 1184, 10.1182/blood.V96.3.1184 Rooney, 1998, Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients, Blood, 92, 1549, 10.1182/blood.V92.5.1549 Haque, 2002, Treatment of Epstein-Barr virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells, Lancet, 360, 436, 10.1016/S0140-6736(02)09672-1 Herbst, 1996, Epstein-Barr virus in Hodgkin's disease., Sem Cancer Biol, 7, 183, 10.1006/scbi.1996.0025 Mueller, 1989, Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis., N Engl J Med, 320, 689, 10.1056/NEJM198903163201103 Gutensohn, 1980, Epidemiology of Hodgkin's disease, Semin Oncol, 7, 92 Weiss, 1989, Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease, N Engl J Med, 320, 502, 10.1056/NEJM198902233200806 Jarrett, 2002, Viruses and Hodgkin's lymphoma, Ann Oncol, 13, 23, 10.1093/annonc/13.S1.23 Pallesen, 1991, Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease, Lancet, 337, 320, 10.1016/0140-6736(91)90943-J Young, 2000, The expression and function of Epstein-Barr virus encoded latent genes, J Clin Pathol: Molecular Pathology, 53, 238 Anagnostopoulos, 1989, Demonstration of monoclonal EBV genomes in Hodgkin's disease and KI-1 positive anaplastic large cell lymphoma by combined Southern blot and in situ hybridization, Blood, 74, 810, 10.1182/blood.V74.2.810.810 Marafioti, 2000, Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal centre B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription, Blood, 95, 1443, 10.1182/blood.V95.4.1443.004k55_1443_1450 Lukes, 1969, Reed-Sternberg-like cells in infectious mononucleosis, Lancet, 2, 1003, 10.1016/S0140-6736(69)90552-2 Chetty, 1997, Hum Pathol, 28, 493, 10.1016/S0046-8177(97)90040-X Rickinson, 1997, Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection, Ann Rev Immunol, 15, 405, 10.1146/annurev.immunol.15.1.405 Roskrow, 1998, Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease, Blood, 91, 2925, 10.1182/blood.V91.8.2925.2925_2925_2934 van Baarle, 2001, Dysfunctional Epstein-Barr virus (EBV)-specific CD8+ T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hogkin lymphoma, Blood, 98, 146, 10.1182/blood.V98.1.146 Beral, 1991, AIDS associated non-Hodgkin Lymphoma, Lancet, 337, 805, 10.1016/0140-6736(91)92513-2 MacMahon, 1991, Epstein-Barr virus in AIDS-related primary central nervous system lymphoma, Lancet, 338, 969, 10.1016/0140-6736(91)91837-K Cinque, 1993, Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDS-related lymphoma of the central nervous system, Lancet, 342, 398, 10.1016/0140-6736(93)92814-A Kirk, 2001, Non-Hodgkin lymphoma in HIV-infected patients in era of highly active antiretroviral therapy, Blood, 98, 3406, 10.1182/blood.V98.12.3406 Hoffman, 2001, Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery, AIDS, 15, 2119, 10.1097/00002030-200111090-00007 Powles, 2000, HIV-associated Hodgkin's disease, Int J STD AIDS, 11, 492, 10.1258/0956462001916362 Grulich, 2002, Rates of non AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis, AIDS, 16, 1155, 10.1097/00002030-200205240-00009 Greenspan, 1985, Replication of Epstein-Barr virus within the epithelial cells of oral hairy leukoplakia: virus replication in the absence of a detectable latent phase, N Engl J Med, 313, 1564, 10.1056/NEJM198512193132502 Itin, 1988, Oral hairy leuloplakia in a HIV-negative renal transplant patient: a marker for immunosuppression?, Dermatologica, 177, 126, 10.1159/000248529 Greenspan, 1989, Oral hairy leukoplakia in an HIV-negative renal transplant recipient, Oral Pathol, 18, 32, 10.1111/j.1600-0714.1989.tb00729.x Flückiger, 1994, Oral hairy leukoplakia in a patient with ulcerative colitis, Gastroenterology, 106, 506, 10.1016/0016-5085(94)90612-2 Niedobitek, 1991, Epstein-Barr virus infection in oral hairy leukoplakia: virus replication in the absence of a detectable latent phase, J Gen Virol, 72, 3035, 10.1099/0022-1317-72-12-3035 Thomas, 1991, Epstein-Barr virus gene expression and epithelial cell differentiation in oral hairy leukoplakia, Am J Path, 139, 1369 Resnick, 1988, Regression of oral hairy leukoplakia after orally administered acyclovir therapy, JAMA, 259, 384, 10.1001/jama.1988.03720030044031 Thorley-Lawson, 1982, Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralising antibodies in vivo, J Virol, 43, 730, 10.1128/JVI.43.2.730-736.1982 Khanna, 1999, EBV structural antigens, gp350 and gp85, as targets for ex vivo virus-specific CTL during acute infectious mononucleosis: potential use of gp350/gp85 CTL epitopes for vaccine design, J Immunol, 162, 3063, 10.4049/jimmunol.162.5.3063 Airey, 2002 Silins, 2001, Asymptomatic primary Epstein-Barr virus infection occurs in the absence of blood T-cell repertoire perturbations despite high levels of systemic viral load, Blood, 98, 3739, 10.1182/blood.V98.13.3739 Wang, 2001, A new animal model for Epstein-Barr virus pathogenesis, Curr Top Microbiol Immunol, 258, 201